者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688331 证券简称：荣昌生物 公告编号：2025-053 荣昌生物制药（烟台）股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 2 日 （二） 股东会召开的地点：山东省烟台市经济技术开发区北京中路 58 号荣昌生 物三期 6134 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 180 | | --- | --- | | 普通股股东人数 | 180 | | 其中：A 股股东人数 | 179 | | 境外上市外资股股东人数 | 1 | | 2、出席会议的股东所持有的表决权数量 | 268,223,021 | | 普通股股东所持有表决权数量 | 268,223,021 | | 其中：A 股股东所持有表决权数量 | 236,190,402 | | 境外上 ...

为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 北京市金杜律师事务所 关于荣昌生物制药（烟台）股份有限公司 2025 年第三次临时股东会 之法律意见书 致：荣昌生物制药（烟台）股份有限公司 北京市金杜律师事务所（以下简称本所）接受荣昌生物制药（烟台）股份有限 公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券法》）、 《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会《上 市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以下简 称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别 行政区和中国台湾省）现行有效的法律、行政法规、规章、规范性文件和现行有效 的公司章程的有关规定，指派律师出席了公司于 2025 年 12 月 2 日召开的 2025 年 第三次临时股东会（以下简称"本次股东会"），并就本次股东会相关事项出具本 法律意见书。 5. 2025 年 11 月 14 日，公司刊登于上海证券交易所网站（www.sse.com.cn） 的《荣昌生物制药（烟台）股份有限公司第二届董事会第三十一次会议决议公告》； 6 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 榮昌生物製藥（煙台）股份有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09995 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and growth in revenue, while also facing challenges in net profit, indicating a mixed financial performance in the biopharmaceutical sector. Group 1: Stock Performance - On December 2, Rongchang Biopharmaceuticals' stock fell by 2.09%, trading at 93.25 CNY per share with a total market capitalization of 52.566 billion CNY [1] - The stock has increased by 209.70% year-to-date, with a 6.57% rise over the last five trading days, but has seen a decline of 3.61% over the last 20 days and 3.69% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on June 26, where it recorded a net buy of -137 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion CNY, reflecting a year-on-year growth of 42.27% [3] - The net profit attributable to shareholders was -551 million CNY, showing a year-on-year increase of 48.60% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average number of circulating shares per person decreased by 15.54% to 10,639 shares [3] - The second-largest shareholder is Hong Kong Central Clearing Limited, holding 8.8418 million shares, a decrease of 510,800 shares from the previous period [4] - New shareholders include Guangfa Medical Care Stock A, which holds 3.9875 million shares [4]

Group 1 - BlackRock reduced its stake in Rongchang Biologics (09995) by 185,500 shares at a price of HKD 81.6411 per share, totaling approximately HKD 15.1444 million [1] - After the reduction, BlackRock's latest shareholding stands at approximately 10.411 million shares, representing a holding percentage of 4.99% [1]

Group 1 - BlackRock reduced its stake in Rongchang Biologics (09995) by 185,500 shares at a price of HKD 81.6411 per share, totaling approximately HKD 15.1444 million [1] - After the reduction, BlackRock's remaining shareholding is approximately 10.4111 million shares, representing a stake of 4.99% [1]

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.09% on November 28, with Rongchang Biopharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Biopharmaceutical Sector Performance - Rongchang Biopharmaceutical (688331) closed at 99.70, with a rise of 3.85% and a trading volume of 71,200 shares, amounting to a transaction value of 708 million yuan [1] - Wanzhe Co., Ltd. (000534) saw a closing price of 20.53, increasing by 2.80% with a trading volume of 121,900 shares, totaling 248 million yuan [1] - Kanghua Biopharmaceutical (300841) closed at 81.81, up 2.10%, with a trading volume of 25,700 shares and a transaction value of 208 million yuan [1] - Other notable performers included Nearshore Protein (688137) at 42.25 (+1.81%), and Wofoo Biopharmaceutical (300357) at 31.49 (+1.68%) [1] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 533 million yuan from institutional investors, while retail investors contributed a net inflow of 300 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Kanghong Pharmaceutical (002773) experienced a net inflow of 4.21 million yuan from institutional investors, while it faced a net outflow of 4.38 million yuan from speculative funds [3] - Notable net inflows from retail investors were observed in stocks like Nuozhilan (920047) with 2.51 million yuan, while stocks like Baik Biopharmaceutical (688276) faced net outflows from retail investors [3]

Core Viewpoint - Rongchang Biopharmaceutical's H-shares have seen a significant increase, with a rise of 5.05% on the previous trading day and an additional 6.68% increase today, reaching 91 HKD [1] Industry Summary - The current wave of innovative drugs is being driven by Chinese companies, particularly in areas such as ADC (Antibody-Drug Conjugates), dual antibodies, second-generation IO (Immuno-Oncology), and GLP-1 [1] - Chinese innovative drug research and development is leading in these fields, with numerous innovative products beginning to "read out" data [1] - The continuous emergence of new technologies and targets, along with ongoing business development (BD) transactions, is expected to further uncover and price the value of early innovation pipelines in Chinese pharmaceutical companies [1]

Core Viewpoint - Rongchang Biologics (09995) experienced a significant stock increase, rising over 7% in the afternoon trading session, with a current price of 90.75 HKD and a trading volume of 319 million HKD, indicating strong market interest and potential investor confidence [1]. Group 1: Clinical Research and Product Development - At the 2025 ESMO annual meeting, clinical research results were published showing that Vidisicimab combined with Toripalimab outperformed chemotherapy as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma [1]. - Yongxing Securities reported that the combination therapy of Vidisicimab demonstrates excellent efficacy, marking a significant change in the treatment landscape for urothelial carcinoma [1]. - CITIC Construction Investment noted that in 2025, the core product Taitasip will rapidly expand after receiving approval for new indications, and the data for the combination treatment with Vidisicimab is promising [1]. Group 2: Pipeline and Market Position - The application for the DME indication of RC28 has been accepted, indicating progress in the company's pipeline [1]. - Among the pipeline products, RC148 has received breakthrough therapy designation, with continuous validation of its clinical data [1]. - Overall, the company is accelerating its commercialization process and has a well-structured pipeline, suggesting a positive outlook for future development [1].

Core Viewpoint - Rongchang Biopharmaceutical (09995) experienced a significant stock increase, rising over 7% in the afternoon trading session, with a current price of 90.75 HKD and a trading volume of 319 million HKD, indicating strong market interest and confidence in the company's future prospects [1] Group 1: Clinical Research and Product Development - The 2025 ESMO annual meeting presented clinical research results showing that Vidisicimab combined with Toripalimab outperforms chemotherapy as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma [1] - Yongxing Securities reported that the combination therapy of Vidisicimab demonstrates excellent immunotherapy efficacy, marking a significant change in the treatment landscape for urothelial carcinoma [1] - CITIC Securities highlighted that in 2025, the core product Taitasip will rapidly expand after receiving approval for new indications, and the data for the combination treatment of Vidisicimab is outstanding [1] Group 2: Pipeline and Market Position - The application for the DME indication of RC28 has been accepted, indicating progress in the company's pipeline [1] - The investigational drug RC148 has received breakthrough therapy designation, with continuous validation of its clinical data, suggesting strong potential for future market success [1] - Overall, the company is accelerating its commercialization process and has a well-structured pipeline, which bodes well for its future development [1]